Title : Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Pub. Date : 2007 Oct 15

PMID : 17727820






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 One strategy is to develop subtype-selective nicotinic receptor (nAChR) antagonists that inhibit nicotine-evoked dopamine (DA) release, the primary neurotransmitter involved in nicotine reward. Nicotine cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus
2 One strategy is to develop subtype-selective nicotinic receptor (nAChR) antagonists that inhibit nicotine-evoked dopamine (DA) release, the primary neurotransmitter involved in nicotine reward. Nicotine cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus
3 TMPD completely inhibited (IC(50)=500 nM) nicotine-evoked DA release from superfused rat striatal slices, suggesting that TMPD acts as a nAChR antagonist at more than one subtype. Nicotine cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus